Skip to main content
. Author manuscript; available in PMC: 2025 Feb 1.
Published in final edited form as: Eur Urol Oncol. 2023 Jul 11;7(1):83–90. doi: 10.1016/j.euo.2023.05.013

Table 7 –

Complete response to treatment within the 1st year

RT + paclitaxel +
trastuzumab (n = 18)
RT + paclitaxel (n = 37)
n (%) 95% CI n (%) 95% CI
Complete response 13 (72.2) (46.5%, 90.3%) 25 (67.6) (50.2%, 82.0%)
No response 5 (27.8) 12 (32.4)

CI = confidence interval; RT = radiotherapy.

Ten patients were not evaluable for response; the reasons are as follows: ten patients died without a response evaluation (two trastuzumab patient and eight no trastuzumab patients).